CBS62logoNEW2013_blue_final_header_White wwj950-sm2011b 971-ticket-35smb 35h_CBSSportsRad_Detroit

Cerenis Therapeutics

cerenis

Cerenis Appoints Non-Executive Director, CMO

Cerenis Therapeutics, the pharma company developing new high-density lipoprortein therapies for cardiovascular and metabolic diseases, Tuesday appointed Richard C. Pasternak to the board of directors and John F. Paolini, M.D., as Chief Medical Officer.

WWJ Newsradio 950–11/22/2011

AP PHOTO -- DO NOT USE

Cerenis Initiates Phase 2 Study of Coronary Syndrome Treatment

Cerenis Therapeutics, the pharma startup with offices in Toulouse, France and Portage, Tuesday announced the start of a Phase 2 clinical trial of its lead drug candidate, CER-001, in patients with acute coronary syndrome.

03/15/2011

Follow

Get every new post delivered to your Inbox.

Join 1,929 other followers